Impact of adalimumab treatment on patient‐reported outcomes: Results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis

References

• Bren L. Psoriasis: more than cosmetic. Accessed July 27, 2007. URL: http://www.fda.gov/fdac/features/2004/2504_psoriasis.html
   Google Scholar
• Camp R. D. R. Psoriasis. Textbook of dermatology, R. H Champion, J. L Burton, D. A Burns, S. M Breathnach. Blackwell Scientific, Boston 1998; 1589–649, 6th ed. Vol. 2.
   Google Scholar
• De Arruda L. H., De Moraes A. P. The impact of psoriasis on quality of life. Br J Dermatol 2001; 144((suppl 58))33–6
   PubMedGoogle Scholar
• Finlay A. Y. Quality of life assessments in dermatology. Semin Cutan Med Surg 1998; 17: 291–6
   PubMed Web of Science ®Google Scholar
• Rapp S. R., Cottrell C. A., Leary M. R. Social coping strategies associated with quality of life decrements among psoriasis patients. Br J Dermatol 2001; 145: 610–16
   PubMed Web of Science ®Google Scholar
• Wahl A. The impact of psoriasis on psychosocial life domains: a review. Scand J Caring Sci 1997; 11: 243–9
   PubMedGoogle Scholar
• Weiss S. C., Kimball A. B., Liewehr D. J., Blauvelt A., Turner M. L., Emanual E. J. Quantifying the harmful effect of psoriasis on health‐related quality of life. J Am Acad Dermatol 2002; 47: 512–18
   PubMed Web of Science ®Google Scholar
• Krueger G. G., Koo J., Lebwohl M., Menter A., Stern R. S., Rolstad T. The impact of psoriasis on quality of life: Results of a 1998 National Psoriasis Foundation patient‐membership survey. Arch Dermatol 2001; 137: 280–4
   PubMed Web of Science ®Google Scholar
• Krueger G. G., Feldman S. R., Camisa C., Duvic M., Elder J. T., Gottlieb A. B. Two considerations for patients with psoriasis and their clinicians: What defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis?. J Am Acad Dermatol 2000; 43((2 Pt 1))281–5
   PubMedGoogle Scholar
• Feldman S. R., Menter A., Koo J. Y. Improved health‐related quality of life following a randomized controlled trial of alefacept treatment in patients with chronic plaque psoriasis. Br J Dermatol 2004; 150: 317–26
   PubMed Web of Science ®Google Scholar
• Finlay A. Y., Salek M. S., Haney J. Intramuscular alefacept improves health‐related quality of life in patients with chronic plaque psoriasis. Dermatology 2003; 206: 307–15
   PubMed Web of Science ®Google Scholar
• Gordon K. B., Papp K. A., Hamilton T. K., Walicke P. A., Dummer W., Li N., et al. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA 2003; 290: 3073–80
   PubMed Web of Science ®Google Scholar
• Gottlieb A. B., Matheson R. T., Lowe N., Krueger G. G., Kang S., Goffe B. S., et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 2003; 139: 1627–32; discussion 1632
   PubMed Web of Science ®Google Scholar
• Leonardi C. L., Powers J. L., Matheson R. T., Goffe B. S., Zitnik R., Wang A., et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003; 349: 2014–22
   PubMed Web of Science ®Google Scholar
• Menter A., Kosinski M., Bresnahan B. W., Papp K. A., Ware J. E, Jr. Impact of efalizumab on psoriasis‐specific patient‐reported outcomes. Results from three randomized, placebo‐controlled clinical trials of moderate to severe plaque psoriasis. J Drugs Dermatol 2004; 3: 27–38
   PubMedGoogle Scholar
• Calabrese L. H. Molecular differences in anticytokine therapies. Clin Exp Rheumatol 2003; 21: 241–8
   PubMed Web of Science ®Google Scholar
• Gordon K. B., Langley R. G., Leonardi C., Toth D., Menter M. A., Kang S., et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double‐blind, randomized controlled trial and open‐label extension study. J Am Acad Dermatol 2006; 55: 598–606
   PubMed Web of Science ®Google Scholar
• Shikiar R., Langley R. G., Willian M. K., Okun M. M., Revicki D. A. Adalimumab treatment is associated with improvement in health‐related quality of life in psoriasis: patient‐reported outcomes from a phase II randomized controlled trial. J Dermatolog Treat 2007; 18: 25–31
   PubMed Web of Science ®Google Scholar
• Menter A., Tyring S. K., Gordon K., Kimball A. B., Leonardi C. L., Langley R. G., et al. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol, 10 October 2007 [epub ahead of print].10.1016/j.jaad.2007.09.010.
   Google Scholar
• Finlay A. Y., Khan G. K. Dermatology Life Quality Index (DLQI): A simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210–16
   PubMed Web of Science ®Google Scholar
• Badia X., Mascaro J. M., Lozano R. Measuring health‐related quality of life in patients with mild to moderate eczema and psoriasis: Clinical validity, reliability and sensitivity to change of the DLQI. The Cavide Research Group. Br J Dermatol 1999; 141: 698–702
   PubMed Web of Science ®Google Scholar
• Lewis V., Finlay A. Y. 10 years experience of the Dermatology Life Quality Index (DLQI). J Investig Dermatol Symp Proc 2004; 9: 169–80
   PubMed Web of Science ®Google Scholar
• Shikiar R., Bresnahan B. W., Stone S. P., Thompson C., Koo J., Revicki D. A. Validity and reliability of patient reported outcomes used in Psoriasis: Results from two randomized clinical trials. Health Qual Life Outcomes 2003; 1: 53
   PubMedGoogle Scholar
• Shikiar R., Willian M. K., Okun M. M., Thompson C. S., Revicki D. A. The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: Results of a phase II study. Health Qual Life Outcomes 2006; 4: 71
   PubMed Web of Science ®Google Scholar
• Feldman S. R., Gordon K. B., Bala M., Evans R., Li S., Dooley L. T., et al. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: A double‐blind placebo‐controlled trial. Br J Dermatol 2005; 152: 954–60
   PubMed Web of Science ®Google Scholar
• Ortonne J. P., Shear N., Shumack S., Henninger E., CLEAR Multinational Study Group. Impact of efalizumab on patient‐reported outcomes in high‐need psoriasis patients: Results of the international, randomized, placebo‐controlled Phase III Clinical Experience Acquired with Raptiva (CLEAR) trial [NCT00256139]. BMC Dermatol 2005; 5: 13
   PubMedGoogle Scholar
• Ware J. E., Kosinski M. K., Keller S. D. SF‐36 Physical and Mental Health Summary Scales: A user's manual. The Health Institute, New England Medical Center, Boston 1994
   Google Scholar
• Wahl A., Loge J. H., Wiklund I., Hanestad B. R. The burden of psoriasis: A study concerning health‐related quality of life among Norwegian adult patients with psoriasis compared with general population norms. J Am Acad Dermatol 2000; 43((5 Pt 1))803–8
   PubMedGoogle Scholar
• Reilly M. C., Zbrozek A. S., Dukes E. M. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 1993; 4: 353–65
   PubMed Web of Science ®Google Scholar
• Kosinski M., Zhao S. Z., Dedhiya S., Osterhaus J. T., Ware J. E Jr. Determining minimally important changes in generic and disease‐specific health‐related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum 2000; 43: 1478–87
   PubMed Web of Science ®Google Scholar
• Kosinski M., Kujawski S. C., Martin R., Wanke L. A., Buatti M. C., Ware J. E Jr., et al. Health‐related quality of life in early rheumatoid arthritis: Impact of disease and treatment response. Am J Manag Care 2002; 8: 231–40
   PubMed Web of Science ®Google Scholar
• Revicki D. A., Cella D., Hays R. D., Sloan J. A., Lenderking W. R., Aaronson N. K. Responsiveness and minimal important differences for patient reported outcomes. Health Qual Life Outcomes 2006; 4: 70
   PubMed Web of Science ®Google Scholar
• Norman G. R., Sloan J. A., Wyrwich K. W. Interpretation of changes in health‐related quality of life: The remarkable universality of half a standard deviation. Med Care 2003; 41: 582–92
   PubMed Web of Science ®Google Scholar